CXCL8 and melanoma: Subsequently, the phase II trial CALM, with CAVATEK as a monotherapy against advanced melanoma patients, demonstrated that the virus induced antitumor responses, as evidenced by increased expression levels of IL-8 and IFN-γ in serum samples of melanoma patients following viral administration [120].